137693-34-6

Usage

Uses

Used in Pharmaceutical Industry:
N-methylpyrrolidine-2-carboxamide is used as a solvent for the production of pharmaceuticals, facilitating the manufacturing process by dissolving a wide range of substances, which is crucial for the synthesis of various drugs.
Used in Polymer Industry:
In the polymer industry, N-methylpyrrolidine-2-carboxamide serves as a solvent, aiding in the processing and production of polymers by enabling the dissolution of polymeric materials, thus improving their workability and performance.
Used in Electronics Industry:
N-methylpyrrolidine-2-carboxamide is utilized as a solvent in the electronics industry, particularly for cleaning and degreasing applications, due to its ability to dissolve a broad spectrum of substances, ensuring the removal of contaminants and residues from electronic components.
Used in General Industrial Applications:
Beyond specific industries, N-methylpyrrolidine-2-carboxamide is used as a general solvent for various industrial processes, capitalizing on its solvency and low volatility to dissolve substances and facilitate manufacturing tasks.
Despite its widespread use, N-methylpyrrolidine-2-carboxamide has faced regulatory scrutiny due to concerns about its potential health and environmental impacts. As a result, there is an ongoing search for alternative solvents that can offer similar benefits without the associated risks.

Upstream product

• 144829-96-9 1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxylic acid 
• 88815-87-6 Boc-Pro-NHMe 
• 15761-39-4 N-tert-butoxycarbonyl-proline 
• 5626-64-2 DL-Pro-NCA 
• 74-89-5 methylamine 

Downstream Products

• 53933-35-0 Piv-L-Pro-NHMe 
• 53933-35-0 Piv-Pro-NHMe 

Relevant academic research and scientific papers

IDO inhibitor as well as preparation method and application thereof

The present invention provides pharmaceutically acceptable salts, isomers, racemates, diastereomers, and pharmaceutical compositions of Formula I, Formula II, Formula III, or Formula IV and application thereof in treatment of indoleamine-(2,3)-dioxygenase-related diseases, specifically in the treatment of tumors, Alzheimer's disease, depression, cataracts and other various serious diseases; wherein R, R2, W and other groups are as shown in the specification. Preliminary drug activity studies show that the compounds have significant IDO inhibitory activity. Simultaneously, SD rats are used as test animals, concentrations of the compounds in the plasma at different time points after intragastric administration of the compounds in the rats are detected by LC/MS/MS method, pharmacokinetic behaviors of the compounds in the bodies of the rats are studied, results showed that the compounds have a significant pharmacokinetic absorption effect and have a good clinical application prospect.

Synthesis and unexpected oxidization of the tricyclic core of ugibohlin, isophakellin, and styloguanidine

A series of 4-substituted 5,6,7,9-tetrahydropyrrolo[2,3-f]indolizin-9-ones, representing the tricyclic core skeleton of ugibohlin, isophakellin, and styloguanidine, were synthesized via an intramolecular Vilsmeier-Haack reaction. This reaction allows the chemoselective C-C bond formation between the pyrrole C3 and proline C5 of N-[(pyrrol-2-yl)carbonyl]prolinamides to construct the B-ring without the protection of the pyrrole nitrogen. Unexpected oxidizative property of the tricyclic core skeleton was observed, which could illuminate understanding of the biological formation of these marine secondary metabolites.

CYCLOBUTENEDIONE DERIVATIVES

The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.

ENANTIOMERIC QUANTIFICATIONS OF AMINO ACIDS THROUGH THEIR Nα-ACYL AMIDES BY GAS CHROMATOGRAPHY.

Apparent separation of 1.1 or higher on Chirasil Val III can be obtained for Nα-acyl N-alkyl aminoacid amides allowing the use of short capillary gas chromatographic columns.A clean derivatization protocol without racemization is described, proceding through the NCA derivatives that are prepared from "in situ" silylated amino acids with trimethylsilyl cyanide.